Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,001 Shares of Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,001 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the completion of the transaction, the chief operating officer owned 4,095 shares in the company, valued at approximately $204,545.25. This trade represents a 32.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Monday, August 31st, Liane Rae Teplitsky purchased 1,024 shares of Pulse Biosciences stock. The shares were acquired at an average price of $48.80 per share, for a total transaction of $49,971.20.
• On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The stock was bought at an average price of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Trading Up 1.1%

NASDAQ:PLSE traded up $0.59 during trading hours on Wednesday, hitting $52.68. 977,767 shares of the company were exchanged, compared to its average volume of 461,050. The stock has a market capitalization of $3.65 billion, a price-to-earnings ratio of -44.64 and a beta of 1.63. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $54.39. The company has a fifty day simple moving average of $36.93 and a 200 day simple moving average of $27.60.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities research analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PLSE. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research note on Monday, August 10th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Needham & Company LLC assumed coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulse Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $28,000. Tower Research Capital LLC TRC increased its holdings in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Pulse Biosciences during the second quarter worth about $158,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.